Diagnosis of Exocrine Pancreatic Insufficiency

被引:37
作者
Phil A. Hart
Darwin L. Conwell
机构
[1] The Ohio State University Wexner Medical Center,Section of Pancreatic Disorders, Division of Gastroenterology, Hepatology, & Nutrition
关键词
Exocrine insufficiency; Steatorrhea; Chronic pancreatitis; Pancreatic enzymes; Lipase;
D O I
10.1007/s11938-015-0057-8
中图分类号
学科分类号
摘要
The accurate diagnosis of exocrine pancreatic insufficiency (EPI) helps identify those in need of pancreatic enzyme replacement therapy. Conversely, ruling out EPI identifies those in which additional evaluation should be pursued to explain their symptoms. There are many available tests that can be used to diagnose EPI; however, the tests must be tailored to each clinical scenario. Tests that are convenient but less accurate (e.g., fecal elastase-1, qualitative fecal fat determination) are best suited for patients with a high pretest probability of EPI. In contrast, tests that are highly accurate but more cumbersome (e.g., endoscopic pancreatic function testing, 72-h fecal fat collection) are favored in patients suspected to have mild EPI or an early stage of chronic pancreatitis. Additional research is needed to identify a more convenient means of accurately diagnosing at all stages of EPI.
引用
收藏
页码:347 / 353
页数:6
相关论文
共 104 条
[31]  
Stevens T(2011)The role of fecal elastase-1 in detecting exocrine pancreatic disease Nat Rev Gastroenterol Hepatol 8 405-15
[32]  
Conwell DL(2013)Fecal elastase-1 is useful in the detection of steatorrhea in patients with pancreatic diseases but not after pancreatic resection Pancreatology 13 38-42
[33]  
Zuccaro G(1985)Fecal chymotrypsin: a new diagnostic test for exocrine pancreatic insufficiency in children with cystic fibrosis Clin Biochem 18 233-4
[34]  
Stevens Tyler(2002)Fecal elastase-1 is superior to fecal chymotrypsin in the assessment of pancreatic involvement in cystic fibrosis Pediatrics 110 e7-62
[35]  
Conwell Darwin L(2010)Oral pancreatic enzyme substitution therapy in chronic pancreatitis: is clinical response an appropriate marker for evaluation of therapeutic efficacy? JOP 11 158-undefined
[36]  
Zuccaro Gregory(undefined)undefined undefined undefined undefined-undefined
[37]  
Lewis Steven A(undefined)undefined undefined undefined undefined-undefined
[38]  
Love Thomas E(undefined)undefined undefined undefined undefined-undefined
[39]  
Stevens T(undefined)undefined undefined undefined undefined-undefined
[40]  
Conwell DL(undefined)undefined undefined undefined undefined-undefined